Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
复制标题
作为九个月大墨西哥儿童的主要麻疹免疫接种的气溶胶麻疹疫苗的免疫原性。
DOI：
10.1016/j.vaccine.2005.08.045
复制
发表时间：
2006
期刊：
影响因子：
5.5
通讯作者：
Valdespino-Gómez,JoséLuis
中科院分区：
文献类型：
--
作者：
Wong-Chew,RosaMaría;Islas-Romero,Rocío;García-García,MaríadeLourdes;Beeler,JudyA;Audet,Susette;Santos-Preciado,JoseIgnacio;Gans,Hayley;Lew-Yasukawa,Linda;Maldonado,YvonneA;Arvin,AnnM;Valdespino-Gómez,JoséLuis
已发现，作为学龄儿童的加强剂，气雾剂麻疹疫苗接种比皮下接种具有更强的免疫原性，作为初级剂量，在12个月大的儿童中具有更强的免疫原性。本研究的目的是评价9个月大儿童对气溶胶麻疹疫苗的免疫原性。方法9个月大的婴儿通过气雾剂（103.58CCID50/0.1mL，估计保留剂量102.81CCID50）或皮下注射（104.28CCID50/0.5mL）接种埃德蒙顿-萨格勒布麻疹疫苗；评估细胞和体液免疫及不良事件。结果42%的雾化疫苗接种儿童出现麻疹特异性T细胞增殖反应，而67%的皮下疫苗接种儿童出现麻疹特异性T细胞增殖反应（p=0.01）；刺激指数（SI）分别为4.4±0.7和6.9±1，差异有统计学意义（p=0.05）。气溶胶或皮下免疫后血清转换率分别为33%和92% （p<0.001）。在出现血清学反应的婴儿中，通过中和抗体测定，麻疹几何平均滴度（GMT; 95% CI）在气溶胶疫苗接种者中为215mIU/mL(115-400)，在皮下疫苗接种者中为411mIU/mL (345-490) （p=0.06）。结论气溶胶组9月龄婴儿对麻疹产生细胞和/或体液免疫的比例较低，但麻疹抗体和T细胞反应在麻疹免疫组中相当。反应率的差异可归因于较低的气溶胶剂量。改善气雾剂给药或增加剂量可增强该年龄组初次气雾剂麻疹疫苗的免疫原性。
Aerosol measles vaccination has been found to be more immunogenic than subcutaneous administration as a booster in school aged children, and immunogenic in 12-month-old children as a primary dose. The objective of the study was to evaluate immunogenicity to aerosol measles vaccine in 9-month-old children.METHODSNine-months-old infants received Edmonston-Zagreb measles vaccine by aerosol (103.58CCID50/0.1mL, estimated retained dose 102.81CCID50) or subcutaneous route (104.28CCID50/0.5mL); cellular and humoral immunity and adverse events were assessed.RESULTSMeasles-specific T cell proliferative responses developed in 42% of children given aerosolized vaccine compared with 67% of those who received subcutaneous vaccine (p=0.01); the mean stimulation index (SI) was 4.4±0.7 versus 6.9±1, respectively, (p=0.05). Seroconversion rates were 33 and 92% after aerosol or subcutaneous immunization (p<0.001). Among infants who developed serologic responses, measles geometric mean titers (GMT; 95% CI) by neutralizing antibody assay were 215mIU/mL (115–400) in aerosol vaccine recipients and 411mIU/mL (345–490) in those given subcutaneous vaccine (p=0.06).CONCLUSIONSThe proportion of 9-month-old infants who developed cellular and/or humoral immunity to measles was lower in the aerosol group but measles antibody and T cell responses were comparable among those who developed measles immunity. Differences in response rates are attributable to the lower aerosol dose. Improving aerosol delivery or increasing the dose may enhance immunogenicity of primary aerosol measles vaccination in this age group.